GLP-1 microdosing, explained

What people mean by microdosing

GLP-1 medications like semaglutide and tirzepatide are usually started at a low dose and stepped up every few weeks toward a higher working dose. “Microdosing” usually means staying at a low dose for longer instead of stepping up on the standard schedule.

On Vitascend's microdose plans that means semaglutide at 0.25 mg a week, or tirzepatide at 2.5 mg a week, for three months. Those are the same doses most people start on anyway; the difference is not moving up.

Why some people choose it

People who ask about microdosing usually want one of these:

• A gentler start, with a better chance of avoiding nausea and stomach upset
• A lower monthly cost while they see how their body responds
• Help with appetite and cravings without aiming for large, fast weight loss
• A lower dose to stay on after reaching their goal (a decision for their clinician)

What the evidence does and doesn't say

The large trials behind these medications studied the full, stepped-up doses of the FDA-approved products, not long-term low doses. There isn't much research on staying at a starting dose for months, so it's honest to say that microdosing is a practical approach some clinicians use rather than a separately proven treatment.

Lower doses generally mean fewer side effects and, for many people, less weight lost than the higher doses studied in trials. Results vary from person to person.

How it works on Vitascend

You pick the microdose plan when you start your visit, and a licensed clinician decides whether it's appropriate for you. If you want to move up later, you don't need a new visit: your clinician reviews how it's going at your 90-day check-in and can move you to a standard plan.

Compounded semaglutide and tirzepatide are not FDA-approved. The same safety rules apply at any dose, including not taking them with a personal or family history of medullary thyroid cancer or MEN 2, or while pregnant.